BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11150750)

  • 1. 9:30-9:45. Preliminary Evaluation of F-18 Fluorocholine (FCH) as a PET Tumor Imaging Agent.
    Coleman R; DeGrado T; Wang S; Baldwin S; Orr M; Reiman R; Price D
    Clin Positron Imaging; 2000 Jul; 3(4):147. PubMed ID: 11150750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
    Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
    J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
    DeGrado TR; Coleman RE; Wang S; Baldwin SW; Orr MD; Robertson CN; Polascik TJ; Price DT
    Cancer Res; 2001 Jan; 61(1):110-7. PubMed ID: 11196147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.
    DeGrado TR; Baldwin SW; Wang S; Orr MD; Liao RP; Friedman HS; Reiman R; Price DT; Coleman RE
    J Nucl Med; 2001 Dec; 42(12):1805-14. PubMed ID: 11752077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
    How Kit N; Dugué AE; Sevin E; Allouache N; Lesaunier F; Joly F; Aide N
    Nucl Med Commun; 2016 Apr; 37(4):348-55. PubMed ID: 26642435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.
    Talbot JN; Gutman F; Fartoux L; Grange JD; Ganne N; Kerrou K; Grahek D; Montravers F; Poupon R; Rosmorduc O
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1285-9. PubMed ID: 16802155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence.
    Spaeth N; Wyss MT; Weber B; Scheidegger S; Lutz A; Verwey J; Radovanovic I; Pahnke J; Wild D; Westera G; Weishaupt D; Hermann DM; Kaser-Hotz B; Aguzzi A; Buck A
    J Nucl Med; 2004 Nov; 45(11):1931-8. PubMed ID: 15534065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Liver Disease and the Detection of Hepatocellular Carcinoma by [(18)F]fluorocholine PET/CT.
    Kwee SA; Wong LL; Hernandez BY; Chan OT; Sato MM; Tsai N
    Diagnostics (Basel); 2015; 5(2):189-99. PubMed ID: 26090216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of
    Quaquarini E; D'Ambrosio D; Sottotetti F; Gallivanone F; Hodolic M; Baiardi P; Palumbo R; Vellani C; Canevari C; Bernardo A; Castiglioni I; Porta C; Trifirò G
    Contrast Media Mol Imaging; 2019; 2019():4325946. PubMed ID: 31049043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism?
    Michaud L; Burgess A; Huchet V; Lefèvre M; Tassart M; Ohnona J; Kerrou K; Balogova S; Talbot JN; Périé S
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4531-6. PubMed ID: 25215560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-RB390: innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via positron emission tomography (PET).
    Bertolini R; Goepfert C; Andrieu T; Nichols S; Walter MA; Frey FJ; McCammon JA; Frey BM
    Prostate; 2015 Mar; 75(4):348-59. PubMed ID: 25358634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
    Colombié M; Campion L; Bailly C; Rusu D; Rousseau T; Mathieu C; Ferrer L; Rousseau N; Kraeber-Bodéré F; Rousseau C
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1784-93. PubMed ID: 26194716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
    Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Talbot JN; Garderet L
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1995-2004. PubMed ID: 27121691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat.
    Spaeth N; Wyss MT; Pahnke J; Biollaz G; Lutz A; Goepfert K; Westera G; Treyer V; Weber B; Buck A
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):673-82. PubMed ID: 16538503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo studies with [(18)F]fluorocholine on digestive tumoral cell lines and in an animal model of metastasized endocrine tumor.
    Nejjari M; Kryza D; Poncet G; Roche C; Perek N; Chayvialle JA; Le Bars D; Scoazec JY; Janier M; Borson-Chazot F
    Nucl Med Biol; 2008 Jan; 35(1):123-30. PubMed ID: 18158951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of
    Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
    Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
    Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
    J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.